Targetable mutation detection in tumor tissue using next-generation sequencing (NGS) by the GeneseeqPrimeTM panel (Nanjing Geneseeq Technology Inc., Nanjing, China) [8] revealed EGFR exon 18 p.G719S mutation and EGFR exon 20 p.S768I mutation. This evidence concerns the gene EGFR and neoplasm.